Investor Alert

London Markets Open in:

Ligand Pharmaceuticals Inc.



After Hours

 --Quotes are delayed by 20 min

Sep 24, 2020, 4:41 p.m.





0.00 0.00%


Volume 1,103

Quotes are delayed by 20 min


Previous close

$ 93.18

$ 94.32


+1.14 +1.22%

Day low

Day high




52 week low

52 week high




Annual Financials for Ligand Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue 71.91M108.97M141.1M251.45M120.28M
Cost of Goods Sold (COGS) incl. D&A 5.81M16.21M17.49M22.13M53.58M
COGS excluding D&A 3.18M4.92M4.97M5.44M9.85M
Depreciation & Amortization Expense 2.63M11.29M12.52M16.69M43.73M
Depreciation 227,000647,000400,000900,0001.5M
Amortization of Intangibles 2.4M10.64M12.12M15.79M42.23M
Gross Income 66.11M92.76M123.62M229.32M66.7M
20152016201720182019 5-year trend
SG&A Expense 37.76M47.84M55.54M65.6M72.42M
Research & Development 13.38M21.22M26.89M27.86M30.54M
Other SG&A 24.38M26.62M28.65M37.73M41.88M
Other Operating Expense -----
Unusual Expense (21.39M)4.07M(620,000)(5.4M)12.8M
EBIT after Unusual Expense 49.74M40.85M620,000169.13M(18.52M)
Non Operating Income/Expense 2.53M2.42M1.98M(11.71M)819.59M
Non-Operating Interest Income ---14M28.43M
Equity in Affiliates (Pretax) (5.14M)(23.13M)(2.05M)50.19M2.89M
Interest Expense 11.8M12.18M11.4M48.28M35.75M
Gross Interest Expense 11.8M12.18M11.4M48.28M35.75M
Interest Capitalized -----
Pretax Income 35.33M7.96M57.23M173.33M796.64M
Income Tax (192.12M)10.33M44.68M30.01M167.34M
Income Tax - Current Domestic 18,00033,000111,000424,00092.57M
Income Tax - Current Foreign --261,000(158,000)(66,000)
Income Tax - Deferred Domestic (192.13M)10.29M44.3M29.74M74.83M
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income 227.44M(2.37M)12.56M143.32M629.3M
Minority Interest Expense (2.38M)----
Net Income 229.82M(2.37M)12.56M143.32M629.3M
Extraordinaries & Discontinued Operations -731,000---
Extra Items & Gain/Loss Sale Of Assets -731,000---
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries 229.82M(1.64M)12.56M143.32M629.3M
Preferred Dividends -----
Net Income Available to Common 229.82M(2.37M)12.56M143.32M629.3M
EPS (Basic) 11.61(0.11)0.606.7733.13
Basic Shares Outstanding 19.79M20.83M21.03M21.16M19M
EPS (Diluted) 10.83(0.11)0.535.9631.85
Diluted Shares Outstanding 21.23M20.83M23.48M24.07M19.76M
EBITDA 30.98M56.21M80.6M180.42M38.01M
Link to MarketWatch's Slice.